JOSHUA COHEN to Humans
This is a "connection" page, showing publications JOSHUA COHEN has written about Humans.
Connection Strength
0.224
-
Facial Expansion: A Blueprint for Coverage. Plast Reconstr Surg. 2023 06 01; 151(6):1286-1294.
Score: 0.021
-
Subcutaneous Lateral Temporal Lift. Clin Plast Surg. 2022 Jul; 49(3):365-375.
Score: 0.020
-
Do Cost-Effectiveness Analyses Account for Drug Genericization? A Literature Review and Assessment of Implications. Value Health. 2022 01; 25(1):59-68.
Score: 0.020
-
Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer. J Oncol Pract. 2019 11; 15(11):e948-e956.
Score: 0.017
-
Advances in Upper Extremity Scleroderma Wound Care. Adv Skin Wound Care. 2018 Oct; 31(10):446-455.
Score: 0.016
-
Reducing Postsurgical Wound Complications: A Critical Review. Adv Skin Wound Care. 2017 06; 30(6):272-286.
Score: 0.014
-
Measuring the Value of Prescription Drugs. N Engl J Med. 2015 Dec 31; 373(27):2595-7.
Score: 0.013
-
Gender Considerations in Rhinoplasty. Plast Reconstr Surg. 2023 09 01; 152(3):438e-445e.
Score: 0.006
-
Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions. J Manag Care Spec Pharm. 2023 Mar; 29(3):257-264.
Score: 0.005
-
Are Medical Devices Cost-Effective? Appl Health Econ Health Policy. 2022 03; 20(2):235-241.
Score: 0.005
-
Evidence-Based Medicine in Plastic Surgery: From Then to Now. Plast Reconstr Surg. 2021 Oct 01; 148(4):645e-649e.
Score: 0.005
-
Revisiting Primary Otoplasty: Surgical Approach to the Prominent Ear. Plast Reconstr Surg. 2021 Jul 01; 148(1):28e-31e.
Score: 0.005
-
Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. J Gen Intern Med. 2020 09; 35(9):2629-2636.
Score: 0.004
-
Right Ventricular Dysfunction and the "D"-shaped Left Ventricle. Anesthesiology. 2020 01; 132(1):155.
Score: 0.004
-
Survival after Digit Replantation and Revascularization Is Not Affected by the Use of Interpositional Grafts during Arterial Repair. Plast Reconstr Surg. 2019 03; 143(3):551e-557e.
Score: 0.004
-
Is the Medial Sural Artery Perforator Flap a New Workhorse Flap? A Systematic Review and Meta-Analysis. Plast Reconstr Surg. 2019 02; 143(2):393e-403e.
Score: 0.004
-
Quantifying outcomes for leech therapy in digit revascularization and replantation. J Hand Surg Eur Vol. 2019 May; 44(4):414-418.
Score: 0.004
-
Targeted Nrf2 activation therapy with RTA 408 enhances regenerative capacity of diabetic wounds. Diabetes Res Clin Pract. 2018 May; 139:11-23.
Score: 0.004
-
Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies. Value Health. 2018 07; 21(7):759-761.
Score: 0.004
-
The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):615-623.
Score: 0.004
-
Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. Med Decis Making. 2017 10; 37(7):790-801.
Score: 0.004
-
The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. Appl Health Econ Health Policy. 2017 Feb; 15(1):75-83.
Score: 0.004
-
Linking Costs and Survival in the Treatment of Older Adults With Chronic Myeloid Leukemia: An Analysis of SEER-Medicare Data From 1995 to 2007. Med Care. 2016 Apr; 54(4):380-5.
Score: 0.003
-
Development and Validation of an Assessment of Regional Anesthesia Ultrasound Interpretation Skills. Reg Anesth Pain Med. 2015 Jul-Aug; 40(4):306-14.
Score: 0.003
-
Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1823-9.
Score: 0.003
-
The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. J Natl Cancer Inst. 2015 Aug; 107(8).
Score: 0.003
-
Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood. 2015 Mar 19; 125(12):1866-9.
Score: 0.003
-
Medicare is scrutinizing evidence more tightly for national coverage determinations. Health Aff (Millwood). 2015 Feb; 34(2):253-60.
Score: 0.003
-
Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014 Aug 28; 371(9):796-7.
Score: 0.003
-
Vascular access choice in incident hemodialysis patients: a decision analysis. J Am Soc Nephrol. 2015 Jan; 26(1):183-91.
Score: 0.003
-
Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. Expert Rev Pharmacoecon Outcomes Res. 2013 Aug; 13(4):513-22.
Score: 0.003
-
Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures. Value Health. 2013 Jun; 16(4):629-38.
Score: 0.003
-
Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012 Oct 02; 60(14):1271-7.
Score: 0.003
-
Cost-effectiveness in the contemporary management of critical limb ischemia with tissue loss. J Vasc Surg. 2012 Oct; 56(4):1015-24.e1.
Score: 0.003
-
A primer on cost-effectiveness analyses for vascular surgeons. J Vasc Surg. 2012 Jun; 55(6):1794-800.
Score: 0.003